A recent study tested a new digital therapeutic for effectiveness on both substance abuse and depression.
In 2018 more than 20 million Americans met criteria for substance use disorder, particularly alcohol abuse (73%). During the COVID-19 pandemic, alcohol sales have risen sharply, up 54% from the previous year.
In this Mental Health Minute, Judith J. Prochaska, PhD, MPH points out that the pandemic has made it difficult for patients to seek traditional forms of counseling. She discusses a digital therapeutic that can be an adjunct for traditional therapies, and results from the latest study on the treatment’s efficacy for substance abuse and mood disorders.
Dr Prochaska is a professor in the department of medicine at Stanford University with the Stanford Prevention Research Center and a member of the Stanford Cancer Institute.
Would you recommend a digital therapeutic to your patients? Share comments with your colleagues by emailing PTEditor@mmhgroup.com. Comments may be shared online pending review and editing for style.